Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients
Launched by METHODIST HEALTH SYSTEM · Jan 16, 2024
Trial Information
Current as of July 06, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the levels of donor-derived cell-free DNA (dd-cfDNA) in patients who have received a liver transplant. The goal is to see how these levels relate to the patients' liver health and their need for immunosuppression medication, which helps prevent the body from rejecting the new liver. By understanding the range of dd-cfDNA levels in patients with stable liver function, doctors hope to make better decisions about adjusting medication dosages for liver transplant recipients.
To be eligible for this trial, participants must be at least 18 years old and have undergone a liver transplant. They also need to have at least one documented level of dd-cfDNA. If someone meets these criteria, they may be invited to join the study. Participants can expect to have their dd-cfDNA levels measured, which will help researchers understand more about how to manage their immunosuppression therapy effectively. This study is currently recruiting participants, and it's open to individuals of all genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age: ≥18 years
- • 2. The patient underwent a liver transplant.
- • 3. The patient at least has one level of dd-cfDNA documented
- Exclusion Criteria:
- • Patient not meeting the inclusion criteria will be excluded.
About Methodist Health System
Methodist Health System is a leading healthcare provider dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and scientific inquiry, the organization leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies across various therapeutic areas. Methodist Health System collaborates with healthcare professionals, researchers, and industry partners to enhance the understanding of diseases and develop new treatment modalities, ensuring that cutting-edge therapies are accessible to the communities it serves. Through its clinical trial initiatives, Methodist Health System aims to contribute to the evolving landscape of medicine while prioritizing patient safety and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Patients applied
Trial Officials
Parvez Mantry, MD
Principal Investigator
Methodist Midlothian Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported